{"nctId":"NCT03996369","briefTitle":"Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis","startDateStruct":{"date":"2020-09-15","type":"ACTUAL"},"conditions":["Ulcerative Colitis"],"count":354,"armGroups":[{"label":"Etrasimod 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrasimod"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Etrasimod","otherNames":["APD334"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with ulcerative colitis (UC) â‰¥ 3 months prior to screening\n* Active UC confirmed by endoscopy\n\nExclusion Criteria:\n\n* Severe extensive colitis\n* Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD\n* Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Clinical Remission","description":"Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \\[\\>=\\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"15.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Endoscopic Improvement","description":"Endoscopic improvement was defined as an ES \\<= 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Symptomatic Remission","description":"Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \\>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mucosal Healing","description":"Mucosal healing was defined as an ES \\<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \\[\\<\\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Clinical Response","description":"Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a \\>= 2-point and \\>= 30 percent (%) decrease from Baseline MMS, and a \\>= 1-point decrease from Baseline in RB sub-score or an absolute RB sub-score \\<= 1. Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"41.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Endoscopic Normalization","description":"Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease); higher score indicated more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Symptomatic Remission at Weeks 2, 4 and 8","description":"Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \\>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":null},{"groupId":"OG001","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Complete Symptomatic Remission","description":"Complete symptomatic remission was defined as an SF sub-score = 0 and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Non-invasive Clinical Response","description":"Non-invasive clinical response was defined as a \\>= 30% decrease from Baseline in composite RB and SF sub-scores, and a \\>= 1 point decrease from Baseline in RB sub-score or RB sub-score \\<= 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"41.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.0","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Symptomatic Response","description":"Symptomatic response was defined as a \\>= 30% decrease from Baseline in composite RB and SF score. The SF sub-score ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null},{"groupId":"OG001","value":"41.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"46.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":238},"commonTop":["Anaemia","Headache","Nausea","Pyrexia","Colitis ulcerative"]}}}